Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?

DOI

10.2991/chi.d.190805.001How to use a DOI?

Keywords

Leukemia; Platelets; Diagnosis; Autoimmunity

Abstract

The differences in diagnosis and management between immune thrombocytopenia (ITP) and leukemia are striking. Leukemia diagnosis and management have evolved substantially over the past 30 years and are now relatively precise. The tendency for leukemic cells to be the overwhelming majority of circulating and/or bone marrow cells certainly continues to facilitate developments, as does improved molecular assessment. Furthermore, randomized controlled clinical trials of competing regimens in well-defined populations have advanced treatment as well. Currently, ITP diagnosis and management depend very much on the experience and preferences of the hematologist. There are no unequivocally useful molecular tests, no agreement on which testing needs to be performed, and no consensus on treatment. Future studies using advanced techniques would ideally change this over time but, thus far, progress in ITP has been slow. However, the increasing ability to do single-cell DNA and RNA studies and flow cytometric dissection of small populations of cells could radically change the approach to ITP if critical distinctions were uncovered.

Copyright

© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

TY  - JOUR
AU  - James Bussel
AU  - Oriana Miltiadous
PY  - 2019
DA  - 2019/08/12
TI  - Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?
JO  - Clinical Hematology International
SP  - 173
EP  - 179
VL  - 1
IS  - 4
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190805.001
DO  - 10.2991/chi.d.190805.001
ID  - Bussel2019
ER  -